Association between the severity of OSAHS patients and serum PCSK9 levels

[1] Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology. 2013;177(9):1006–14. PeppardPE YoungT BarnetJH PaltaM HagenEW HlaKM Increased prevalence of sleep-disordered breathing in adults American Journal of Epidemiology 2013 177 9 1006 14 Search in Google Scholar

[2] Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, et al. Prevalence of sleep-disordered breathing in the general population: The HypnoLaus study. The Lancet Respiratory Medicine. 2015;3(4):310–8. HeinzerR VatS Marques-VidalP Marti-SolerH AndriesD TobbackN Prevalence of sleep-disordered breathing in the general population: The HypnoLaus study The Lancet Respiratory Medicine 2015 3 4 310 8 Search in Google Scholar

[3] Tan A, Cheung YY, Yin J, Lim WY, Tan LW, Lee CH. Prevalence of sleep-disordered breathing in a multiethnic Asian population in Singapore: A community-based study. Respirology (Carlton, Vic). 2016;21(5):943–50. TanA CheungYY YinJ LimWY TanLW LeeCH Prevalence of sleep-disordered breathing in a multiethnic Asian population in Singapore: A community-based study Respirology (Carlton, Vic) 2016 21 5 943 50 Search in Google Scholar

[4] Taylor BA, Panza G, Pescatello LS, Chipkin S, Gipe D, Shao W, et al. Serum PCSK9 levels distinguish individuals who do not respond to high-dose statin therapy with the expected reduction in LDL-C. Journal of Lipids. 2014;2014:140723. TaylorBA PanzaG PescatelloLS ChipkinS GipeD ShaoW Serum PCSK9 levels distinguish individuals who do not respond to high-dose statin therapy with the expected reduction in LDL-C Journal of Lipids 2014 2014 140723 Search in Google Scholar

[5] Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, et al. Obstructive sleep apnea and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021;144(3):e56–e67. YeghiazariansY JneidH TietjensJR RedlineS BrownDL El-SherifN Obstructive sleep apnea and cardiovascular disease: A scientific statement from the American Heart Association Circulation 2021 144 3 e56 e67 Search in Google Scholar

[6] Schulz R, Schlüter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic research in cardiology. 2015;110(2):4. SchulzR SchlüterKD LaufsU Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9) Basic research in cardiology 2015 110 2 4 Search in Google Scholar

[7] Yurtseven E, Ural D, Baysal K, Tokgözoğlu L. An update on the role of PCSK9 in atherosclerosis. Journal of Atherosclerosis and Rhrombosis. 2020;27(9):909–18. YurtsevenE UralD BaysalK TokgözoğluL An update on the role of PCSK9 in atherosclerosis Journal of Atherosclerosis and Rhrombosis 2020 27 9 909 18 Search in Google Scholar

[8] Qiu S, Liu D, Zhong J. [Interpretation of French Society of ENT guidelines on the roles of the various treatment options in childhood obstructive sleep apnea-hypopnea syndrome]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of Olinical Otorhinolaryngology, Head, and Neck Surgery. 2020;34(2):97–100. QiuS LiuD ZhongJ [Interpretation of French Society of ENT guidelines on the roles of the various treatment options in childhood obstructive sleep apnea-hypopnea syndrome] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of Olinical Otorhinolaryngology, Head, and Neck Surgery 2020 34 2 97 100 Search in Google Scholar

[9] Tobaldini E, Costantino G, Solbiati M, Cogliati C, Kara T, Nobili L, et al. Sleep, sleep deprivation, autonomic nervous system and cardiovascular diseases. Neuroscience and biobehavioral reviews. 2017;74(Pt B):321–9. TobaldiniE CostantinoG SolbiatiM CogliatiC KaraT NobiliL Sleep, sleep deprivation, autonomic nervous system and cardiovascular diseases Neuroscience and biobehavioral reviews 2017 74 Pt B 321 9 Search in Google Scholar

[10] Zhan Y, Chen R, Yu J. Sleep duration and abnormal serum lipids: the China Health and Nutrition Survey. Sleep medicine. 2014;15(7):833–9. ZhanY ChenR YuJ Sleep duration and abnormal serum lipids: the China Health and Nutrition Survey Sleep medicine 2014 15 7 833 9 Search in Google Scholar

[11] Broussard JL, Chapotot F, Abraham V, Day A, Delebecque F, Whitmore HR, et al. Sleep restriction increases free fatty acids in healthy men. Diabetologia. 2015;58(4):791–8. BroussardJL ChapototF AbrahamV DayA DelebecqueF WhitmoreHR Sleep restriction increases free fatty acids in healthy men Diabetologia 2015 58 4 791 8 Search in Google Scholar

[12] Pan Y, Zhou Y, Shi X, He S, Lai W. The association between sleep deprivation and the risk of cardiovascular diseases: A systematic meta-analysis. Biomedical reports. 2023;19(5):78. PanY ZhouY ShiX HeS LaiW The association between sleep deprivation and the risk of cardiovascular diseases: A systematic meta-analysis Biomedical reports 2023 19 5 78 Search in Google Scholar

[13] Cho SMJ, Koyama S, Honigberg MC, Surakka I, Haidermota S, Ganesh S, et al. Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study. European Heart Journal. 2023;44(36):3456–65. ChoSMJ KoyamaS HonigbergMC SurakkaI HaidermotaS GaneshS Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study European Heart Journal 2023 44 36 3456 65 Search in Google Scholar

[14] Chapman MJ, Stock JK, Ginsberg HN. PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era. Current Opinion in Lipidology. 2015;26(6):511–20. ChapmanMJ StockJK GinsbergHN PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era Current Opinion in Lipidology 2015 26 6 511 20 Search in Google Scholar

[15] Li J, Liang X, Wang Y, Xu Z, Li G. Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis. Molecular Medicine Reports. 2017;16(2):1817–25. LiJ LiangX WangY XuZ LiG Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis Molecular Medicine Reports 2017 16 2 1817 25 Search in Google Scholar

[16] Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D, et al. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation. 2021;143(1):45–61. QiZ HuL ZhangJ YangW LiuX JiaD PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36 Circulation 2021 143 1 45 61 Search in Google Scholar

[17] Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation Cardiovascular Quality and Outcomes. 2011;4(3):337–45. SnidermanAD WilliamsK ContoisJH MonroeHM McQueenMJ de GraafJ A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circulation Cardiovascular Quality and Outcomes 2011 4 3 337 45 Search in Google Scholar

[18] Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation. 2014;130(5):431–41. RashidS TavoriH BrownPE LintonMF HeJ GiunzioniI Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms Circulation 2014 130 5 431 41 Search in Google Scholar

[19] Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338–50. BonacaMP NaultP GiuglianoRP KeechAC PinedaAL KanevskyE Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Circulation 2018 137 4 338 50 Search in Google Scholar

[20] Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. International Journal of Molecular Medicine. 2012;30(4):931–8. TangZ JiangL PengJ RenZ WeiD WuC PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages International Journal of Molecular Medicine 2012 30 4 931 8 Search in Google Scholar

[21] Kysenius K, Muggalla P, Mätlik K, Arumäe U, Huttunen HJ. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cellular and Molecular Life Sciences: CMLS. 2012;69(11):1903–16. KyseniusK MuggallaP MätlikK ArumäeU HuttunenHJ PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling Cellular and Molecular Life Sciences: CMLS 2012 69 11 1903 16 Search in Google Scholar

[22] Liu LS, Bai XQ, Gao Y, Wu Q, Ren Z, Li Q, et al. PCSK9 Promotes oxLDL-Induced PC12 cell apoptosis through the Bcl-2/Bax-Caspase 9/3 signaling pathway. Journal of Alzheimer’s Disease: JAD. 2017;57(3):723–34. LiuLS BaiXQ GaoY WuQ RenZ LiQ PCSK9 Promotes oxLDL-Induced PC12 cell apoptosis through the Bcl-2/Bax-Caspase 9/3 signaling pathway Journal of Alzheimer’s Disease: JAD 2017 57 3 723 34 Search in Google Scholar

[23] Dozio E, Ruscica M, Vianello E, Macchi C, Sitzia C, Schmitz G, et al. PCSK9 expression in epicardial adipose tissue: Molecular association with local tissue inflammation. Mediators of Inflammation. 2020;2020:1348913. DozioE RuscicaM VianelloE MacchiC SitziaC SchmitzG PCSK9 expression in epicardial adipose tissue: Molecular association with local tissue inflammation Mediators of Inflammation 2020 2020 1348913 Search in Google Scholar

[24] Landlinger C, Pouwer MG, Juno C, van der Hoorn JWA, Pieterman EJ, Jukema JW, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. European Heart Journal. 2017;38(32):2499–507. LandlingerC PouwerMG JunoC van der HoornJWA PietermanEJ JukemaJW The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice European Heart Journal 2017 38 32 2499 507 Search in Google Scholar